Assignee
BETA PHARMA INC
US·15 granted patents·6 pending applications·27 citations·filing 2003–2023
Top patents by PatentIndex Score
21 records- 0187US9878994B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2015·Granted Jan 30, 2018·8 cites·32 claims
- 0285US10239864B22-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2018·Granted Mar 26, 2019·5 cites·20 claims
- 0376US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 0476US7078409B2Fused quinazoline derivatives useful as tyrosine kinase inhibitorsBETA PHARMA INC·Filed 2003·Granted Jul 18, 2006·12 cites·16 claims
- 0569US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 0665US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 0761US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 0860US2025276968A18- and 6-substituted pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2023·Application pending·0 cites
- 0959US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 1058US2025250286A1Fused pyrimidine derivatives as kras oncoprotein inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1156US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 1256US9359370B2Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereofBETA PHARMA INC·Filed 2014·Granted Jun 7, 2016·0 cites·13 claims
- 1354US11352341B22H-indazole derivatives as CDK4 and CDK6 inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Jun 7, 2022·0 cites·19 claims
- 1454US2024140948A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1553US12258365B2Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 1652US2023099858A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 1751US2024002365A1Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 1850US12390464B2Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitorsBETA PHARMA INC·Filed 2020·Granted Aug 19, 2025·0 cites·20 claims
- 1946US2022079944A12h-indazole derivatives as therapeutic agents for brain cancers and brain metastasesBETA PHARMA INC·Filed 2020·Application pending·0 cites
- 2044US12595246B2Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereofBETA PHARMA INC·Filed 2020·Granted Apr 7, 2026·0 cites·7 claims
- 2140US9820721B2Aspiration and biopsy needle apparatus and devices and applications thereofBETA PHARMA INC·Filed 2015·Granted Nov 21, 2017·0 cites·38 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →